David Jonathan Bennett

Statistics

Publications

Citations

2.6K

H-Index

Active since

1980

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

United States Military Academy

Quantitative BioSciences

NHS Lanarkshire

Merck Serono Ltd. (United Kingdom)

David Jonathan Bennett is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicinal chemistry, pharmacology, and drug discovery.

ORCID

Publications per year

1980–2024

Publications

An orally available non-nucleotide STING agonist with antitumor activity

Bo‐Sheng Pan, Samanthi A. Perera, Jennifer Piesvaux et al. · Science · 2020 · 660 citations

Medicine, Medicinal Chemistry, Pharmacology +16

Cyclodextrin-Derived Host Molecules as Reversal Agents for the Neuromuscular Blocker Rocuronium Bromide: Synthesis and Structure−Activity Relationships

Julia M. Adam, David Jonathan Bennett, A. Bom et al. · Journal of Medicinal Chemistry · 2002 · 233 citations

Medicine, Medicinal Chemistry, Pharmacology +15

A Selective Synthesis of 2,2-Difluorobicyclo[1.1.1]pentane Analogues: “BCP-F<sub>2</sub>”

Xiaoshen Ma, David L. Sloman, Yongxin Han et al. · Organic Letters · 2019 · 158 citations

Natural Sciences, Chemistry, Medicinal Chemistry +11

General access to cubanes as benzene bioisosteres

Mario P. Wiesenfeldt, James A. Rossi‐Ashton, Ian B. Perry et al. · Nature · 2023 · 156 citations · Full text

Pharmacy, Chemistry, Medicinal Chemistry +13

Discovery of MK-1454: A Potent Cyclic Dinucleotide Stimulator of Interferon Genes Agonist for the Treatment of Cancer

Wonsuk Chang, Michael D. Altman, Charles A. Lesburg et al. · Journal of Medicinal Chemistry · 2022 · 137 citations · Full text

Pharmacy, Oncology, Pharmacology +17

1–5 of 39